IL308488A - CD40L antagonist and its uses in the treatment of lupus nephritis - Google Patents
CD40L antagonist and its uses in the treatment of lupus nephritisInfo
- Publication number
- IL308488A IL308488A IL308488A IL30848823A IL308488A IL 308488 A IL308488 A IL 308488A IL 308488 A IL308488 A IL 308488A IL 30848823 A IL30848823 A IL 30848823A IL 308488 A IL308488 A IL 308488A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- lupus nephritis
- cd40l antagonist
- cd40l
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191514P | 2021-05-21 | 2021-05-21 | |
| US202163235520P | 2021-08-20 | 2021-08-20 | |
| PCT/US2022/030290 WO2022246225A1 (en) | 2021-05-21 | 2022-05-20 | Cd40l antagonist and uses thereof in the treatment of lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308488A true IL308488A (en) | 2024-01-01 |
Family
ID=82100122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308488A IL308488A (en) | 2021-05-21 | 2022-05-20 | CD40L antagonist and its uses in the treatment of lupus nephritis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240084024A1 (https=) |
| EP (1) | EP4340867A1 (https=) |
| JP (1) | JP2024519904A (https=) |
| KR (1) | KR20240012473A (https=) |
| AU (1) | AU2022276507A1 (https=) |
| BR (1) | BR112023024153A2 (https=) |
| CA (1) | CA3219742A1 (https=) |
| IL (1) | IL308488A (https=) |
| MX (1) | MX2023013815A (https=) |
| WO (1) | WO2022246225A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024152001A1 (en) * | 2023-01-13 | 2024-07-18 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome |
| KR20250162587A (ko) * | 2023-03-28 | 2025-11-18 | 비엘라 바이오, 인크. | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753567A1 (en) * | 2011-10-11 | 2020-12-23 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| KR20260016618A (ko) * | 2018-09-26 | 2026-02-03 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2022
- 2022-05-20 AU AU2022276507A patent/AU2022276507A1/en active Pending
- 2022-05-20 JP JP2023571882A patent/JP2024519904A/ja active Pending
- 2022-05-20 BR BR112023024153A patent/BR112023024153A2/pt unknown
- 2022-05-20 MX MX2023013815A patent/MX2023013815A/es unknown
- 2022-05-20 EP EP22731386.3A patent/EP4340867A1/en active Pending
- 2022-05-20 IL IL308488A patent/IL308488A/en unknown
- 2022-05-20 WO PCT/US2022/030290 patent/WO2022246225A1/en not_active Ceased
- 2022-05-20 CA CA3219742A patent/CA3219742A1/en active Pending
- 2022-05-20 KR KR1020237043917A patent/KR20240012473A/ko active Pending
-
2023
- 2023-11-15 US US18/509,836 patent/US20240084024A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022246225A1 (en) | 2022-11-24 |
| CA3219742A1 (en) | 2022-11-24 |
| EP4340867A1 (en) | 2024-03-27 |
| US20240084024A1 (en) | 2024-03-14 |
| MX2023013815A (es) | 2024-01-09 |
| JP2024519904A (ja) | 2024-05-21 |
| BR112023024153A2 (pt) | 2024-02-06 |
| AU2022276507A9 (en) | 2023-12-14 |
| AU2022276507A1 (en) | 2023-12-07 |
| KR20240012473A (ko) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273031A (en) | Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| IL289748A (en) | Heterodimers and methods of using them | |
| SI4014976T1 (sl) | Aprocitentan za uporabo pri zdravljenju hipertenzije in sorodnih bolezni v kombinaciji z valsartanom | |
| LT3806898T (lt) | Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui | |
| SG11202103021VA (en) | Cd40l antagonist and uses thereof | |
| IL308488A (en) | CD40L antagonist and its uses in the treatment of lupus nephritis | |
| IL277404A (en) | C3-binding substances and methods of using them | |
| PL3615035T3 (pl) | Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii | |
| WO2015195863A8 (en) | Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide | |
| IL271464A (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| IL270976A (en) | IL-8 inhibitors for use in the treatment and/or prevention of secondary bacterial infection | |
| GB2615478B (en) | Therapeutic and prophylactic use of microorganisms | |
| IL289758B2 (en) | Proportin inhibitors for use in the prevention and treatment of kidney injury | |
| ZA201903828B (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| HK40107955A (en) | Cd40l antagonist and uses thereof in the treatment of lupus nephritis | |
| IL286149A (en) | Caspase inhibitors and methods of using them | |
| PL3937949T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu upośledzenia funkcji oddechowych | |
| ZA201806864B (en) | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients | |
| PL3797771T3 (pl) | Rebamipid do stosowania w zapobieganiu i leczeniu celiakii | |
| EP3648789C0 (en) | MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY | |
| HK40077345A (en) | Tricyclic janus kinase (jak) inhibitors and their use in the treatment of autoimmune diseases | |
| SG11202101945PA (en) | Peptide therapeutics for the treatment of cancer and uses thereof | |
| AU2018900412A0 (en) | Compositions and their use in the treatment of endometriosis and pain | |
| HK40022380A (en) | Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine | |
| IL313687A (en) | OXER1 antagonists and their uses |